- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02694861
CardioGenesis Transmyocardial Revascularization 1-Year Follow-Up Study
A Multi-Center Single Arm One Year Prospective Follow-Up of Patients Treated With the CryoLife CardioGenesis Holmium:YAG Laser System for Transmyocardial Revascularization (The TMR 365 Study)
The purpose of this study it to collect real world 30-day and 1-year follow-up data for patients undergoing TMR with the CardioGenesis Holmium:YAG Laser System either as a sole therapy procedure or in conjunction with coronary artery bypass graft (CABG) surgery.
The primary objective of this study is to provide ongoing clinical data regarding the characteristics of the patient population undergoing TMR in community practices. Secondary objectives include rates of postoperative mortality and MACE at 30-days and 1-year, and benefit of sustained improvement in angina at 30-days and 1-year.
The study includes two patient populations:
- Registry Group: Patients from selected centers who previously participated in the ANGINA RELIEF Registry and are eligible for a one-year, prospective follow-up;
- Prospective Group: Up to 100 new, prospectively enrolled TMR patients from selected centers.
Study Overview
Status
Conditions
Detailed Description
The study objectives are as follows:
- Track "real world" performance outcomes and physician experience using the CardioGenesis Laser System;
- Further define the disease characteristics of the population being treated;
- Examine transmyocardial revascularization (TMR) usage characteristics, including surgical procedure information, and 30-day and 1-year outcomes;
- Further assess the risk factors for adverse events at 30-days and 1-year;
- Further define MACE rates and angina scores at 30-days and 1-year. To limit the potential for bias, all patients eligible for TMR treatment who meet the Inclusion and Exclusion Criteria will be offered the opportunity to enroll in the study at participating centers.
Primary Endpoint:
- 1-year Canadian Cardiovascular Society (CCS) angina class
Secondary Endpoints:
- All-cause mortality at 30-day and 1-year.
- Rates of major adverse cardiovascular events (MACE) at 30-days and 1-year, defined as the incidence of cardiac-related death, myocardial infarction (Q-wave and non Q-wave), congestive heart failure, cerebrovascular accident, and serious arrhythmia.
The definitions for MACE events are as follows:
- Cardiac-related death: any death that is not clearly attributable to a non-cardiac cause, and includes death due to any of the following: acute myocardial infarction, heart failure, cardiogenic shock, pulmonary edema, cardiac tamponade, arrhythmia, or post-procedural complications (i.e., bleeding).
- Q-wave myocardial infarction: the appearance of new Q waves of 40 or more milliseconds in 2 or more contiguous leads and elevation of CK-MB.
- Non Q-wave myocardial infarction: the elevation of total CK more than twice normal with elevated CK-MB.
- Congestive heart failure: Symptoms of pulmonary vascular congestion or a low output state that is due to left ventricular failure and is new in onset or results in re-hospitalization.
- Cerebrovascular accident: Any sudden development of neurological deficits due to vascular lesions of the brain such as hemorrhage, embolism, or thrombosis that persists for > 24 hours.
- Serious arrhythmia: Supra-ventricular or ventricular arrhythmias that require sustained intravenous pharmacologic treatment, temporary or permanent pacing, or immediate electrical cardioversion or defibrillation. Arrhythmias resulting in syncope, myocardial ischemia, or death are also classified as serious.
- Any other serious operative complications related to the procedure: example: major bleeding requiring transfusion.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32204
- Cardiothoracic and Vascular Surgical Associates
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- TriStar Cardiovascular Surgery
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Registry Group: Previously enrolled in the ANGINA RELIEF Registry; Eligible for a 1-year prospective follow-up (date of TMR procedure performed within 12-18 month follow-up window).
- Prospective Group: Received TMR with the CardioGenesis Laser System; Class IV angina (according to Canadian Cardiovascular Society Angina Scale) prior to TMR; Patients with regions of myocardium in the distal two-thirds of the left ventricle with reversible ischemia and who are not eligible for direct coronary revascularization (e.g., CABG or PTCA).
Exclusion Criteria:
- Registry Group: Date of ANGINA RELIEF Registry TMR procedure performed outside 1-year (12-18 month) follow-up window.
- Prospective Group: Age less than 18 years; Severely unstable angina (un-weanable from intravenous anti-anginals for 48-hours).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Registry Group
Patients previously enrolled in the ANGINA RELIEF Registry who are eligible for a 1-year, prospective follow-up (date of ANGINA RELIEF Registry TMR procedure performed within 12-18 month follow-up window).
|
Prospective Group
A group of up to 100 new, prospectively enrolled patients from active centers that receive TMR with the CardioGenesis Laser System and complete a 30-day and 1-year follow-up.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Canadian Cardiovascular Society (CCS) Angina Class from Baseline (Class IV) at 1 Year.
Time Frame: 1 year
|
Class I: Ordinary physical activity does not cause angina, such as walking and climbing stairs.
Angina with strenuous or rapid or prolonged exertion at work or recreation; Class II: Slight limitation of ordinary activity.
Walking or climbing stairs rapidly, walking uphill, walking or stair climbing after meals, or in cold, or in wind, or under emotional stress, or only during the few hours after awakening.
Walking more than two blocks on the level and climbing more than one flight of ordinary stairs at a normal pace and in normal conditions; Class III: Marked limitation of ordinary physical activity.
Walking one or two blocks on the level and climbing one flight of stairs in normal conditions and at normal pace; Class IV: Inability to carry on any physical activity without discomfort, anginal syndrome may be present at rest.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of all cause mortality
Time Frame: 30 days, 1 year
|
All-cause mortality
|
30 days, 1 year
|
Rates of Major Adverse Cardiovascular Events (MACE)
Time Frame: 30 days, 1 year
|
Defined as the incidence of cardiac-related death, myocardial infarction (Q-wave and non Q-wave), congestive heart failure, cerebrovascular accident, and serious arrhythmia.
|
30 days, 1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TMR1501.001-M (10/15)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Class IV Angina
-
Cardiogenesis Corporation, a wholly-owned subsidiary...Terminated
-
Cardiogenesis Corporation, a wholly-owned subsidiary...CompletedClass IV AnginaUnited States
-
Wuerzburg University HospitalCharite University, Berlin, Germany; Goethe University; RWTH Aachen University; Technical University of Munich and other collaboratorsRecruitingSurgery | ASA Class III/IV Patients | Clinical Decision Support SystemsGermany
-
University of MichiganNational Heart, Lung, and Blood Institute (NHLBI)RecruitingHeart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IVUnited States
-
Comunicare Solutions SAKU Leuven; Jessa Hospital; Cliniques universitaires Saint-Luc- Université Catholique... and other collaboratorsRecruitingHeart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IVBelgium
-
Elpen Pharmaceutical Co. Inc.WithdrawnHeart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IV
-
John ParissisCompletedHeart Failure | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure NYHA Class IV | Heart Failure NYHA Class IGreece
-
University of Turin, ItalyCompletedHeart Failure NYHA Class III | Heart Failure NYHA Class IVItaly
-
NuPulseCVUnknownHeart Failure NYHA Class III | Heart Failure NYHA Class IVUnited States
-
University of LouisvilleThoratec CorporationUnknownHeart Failure NYHA Class III | Heart Failure NYHA Class IVUnited States